valu usd unless otherwis note
view japan sale disappoint unabl sustain
strong sale seen previou quarter lack new medic product
increas competit make us reduc sale expect
favor claim experi across busi help drive
beat capit return remain attract see subdu potenti sale
growth view share expens rel peer
estim chang price target adjust ep
estim primarili reflect upsid
quarter estim fine-tun
estim fine-tun reflect
benefit slightli upwardli revis share repurchas assumpt
partli off-set upwardli revis expens assumpt aflac us
pre-tax op margin estim in-lin long-term guidanc
provid manag previous held investor day
lower price target base estim
end book valu continu see share expens view
limit earn growth expect weaken roe expect
result report oper ep vs last
year beat estim consensu upsid
better expect benefit ratio japan lower expect
corpor loss upsid corpor tax
much weaker expect japan sale amid elev competit
activ japan sale came much weaker expect declin
y/i quarter vs y/i growth estim third-sector
sale declin y/i key factor drive weak includ
sale forc recent start emphas sell refresh
version compani cancer product rel less emphasi
sell core medic product even view slightli
disappoint see cancer sale increas y/i sustain
momentum strong sale neg manag
note elev competit activ japan medic product market
due new entrant low interest rate forc player shift
posit bottom-line ep expect share repurchas
expect better expect aflac us sale
neg disappoint aflac japan sale sign japan
medic product market increasingli competit manag
maintain full year ep guidanc impli ep current
price prior trade day market close estimate unless otherwis note
bloomberg capit market estim upside/downside/target
price target base approxim estim
assum normal new premium growth low-singl
digit incur claim percentag revenu
remain stabl across busi assum us sale
growth y/i japan sale
valuat upsid scenario assum roughli
premium growth across us across
japan busi result enhanc sale
distribut effort assum addit basi point
us margin basi point japan margin
valuat downsid scenario assum
declin us premium declin japan
sale reflect weak econom condit assum
addit basi point lower us margin basi
point lower japan margin result advers loss cost
stori continu await improv
capit return effort us japan energ
sale growth remain low-singl digit
sever year sign improv
japan recent new product roll-out compani
continu struggl gener consist mid-singl
digit sale growth unit ultim think
stori primarili capit return growth
could abid differ lower valuat
current share price well compani compar
roe consist compani
seen meaning earn growth three year tax
reform benefit withstand under-perform rate
reflect elev valuat lack progress earn
driver
sale growth reason optim
us sale manag guidanc y/i
continu reflect on-going restructur salesforc
distribut channel compani japan third sector
sale guidanc depend recent launch
product updat earli result good benefit
like fade fairli quickli
invest cash flow higher-yield us asset mainli
corpor bond use deriv hedg fx risk
compani start use floating-r asset
help off-set hedg cost volatil thu stabil margin
consider capit result japan branch
convers buyback peg billion billion
total capit return includ dividend expect
takeaway quarter
much weaker expect japan sale amid elev competit activ japan
sale came much weaker expect declin y/i quarter vs
y/i growth estim third-sector sale declin y/i key factor drive
weak includ sale forc recent start emphas sell
refresh version compani cancer product rel less emphasi
sell core medic product even view slightli disappoint see
cancer sale increas y/i sustain momentum strong sale
comprehens market effort like pull forward sale recal new
cancer product includ number popular enhanc featur back
larg tv direct market campaign prove success reach
interest buyer along full distribut japan outlet
neg manag note elev competit activ japan medic product
market due new entrant low interest rate forc player shift focu
onto third sector product less interest rate sensit manag
expect similar result lower japan sale growth assumpt
y/i previous third sector sale growth expect
low singl digit year new product develop key growth
longer term potenti new product could launch earli next year
us sale better expect us sale expect
manag maintain guidanc rang full year sale growth though
like closer lower end rang updat model assum y/i
sale growth note sale skew toward time
manag continu focu expand sale broker
grow faster pace ytd off-set rel sluggish sale growth
independ career agent sale declin ytd said
career agent sale channel still contribut roughli us sale
capit portfolio reposit capit return quarter million share
buyback forecast million compani remain commit
billion full year clearli track deliv
million complet far weve seen major boost buy-back activ
anticip coupl year ago branch initi announc capit ratio
firmli excess rang us ratio expect around
year end similarli strong japan around current
compani hedg activ design protect econom valu aflac japan
franchis us dollar term weve long view compani strong capit posit
key attribut stori togeth strong cash flow support
third sector sale growth japan expect low singl digit rang us sale
growth guidanc maintain rang though closer lower end rang share
buyback billion rang also maintain earn guidanc
year remain manag point high end rang
impli someth like per share assum rang isnt exceed
estim price target
adjust ep estim primarili reflect
upsid quarter estim fine-tun
estim fine-tun reflect benefit slightli
upwardli revis share repurchas assumpt partli off-set upwardli revis
expens assumpt aflac us pre-tax op margin estim in-lin longer-
term guidanc provid manag previous held investor day
lower price target base estim end book
valu continu see share expens view limit earn growth
expect weaken roe expect
report oper ep vs last year beat estim
consensu upsid better expect benefit ratio japan
lower expect corpor loss upsid corpor tax
compani report capit market estim
unit report pre-tax oper earn million better
million estim overal japan premium declin y/i quarter yen term
littl better declin estim third-sector product sale decreas
quarter much weaker estim especi follow growth
pre-tax oper margin beat estim upsid
benefit ratio came quarter better estim
million except per-shar figur actualrbc estimatevariancepre-tax oper earningsaflac expens non-insur compani oper oper dilut averag share oper
compani report capit market estim
unit report pre-tax oper earn million essenti in-lin
million estim premium rose billion in-lin
estim us total new annual premium sale increas y/i
littl ahead estim invest incom better expect million
reflect higher float rate benefit ratio better
estim pre-tax oper margin better estim
despit higher expect expens ratio vs
compani report capit market estim
manag continu focu drive sale volum broker channel rather
independ agent remain commit y/i sale growth guidanc
though sale like come closer lower end rang result
million aflac japanactualrbc invest incom realiz foreign currenc futur polici oper benefit oper oper oper earn usactualrbc invest incom realiz foreign currenc futur polici oper benefit oper oper
benefit favor claim experi benefit ratio come though
expect revers note result typic weaker
invest balanc sheet capit
compani complet million share buyback quarter
million forecast corpor result benefit million contribut
compani yen hedg program would off-set within japan result
continu higher interest incom asset transfer part excess capit
drawdown end book valu ex-aoci end quarter per share
price target base upon approxim estim book valu ex-aoci
price book multipl base compani anticip roe
consid expect premium growth well capit return expect
price target consist under-perform rate share current trade
premium compani coverag univers book valu compar
nearest peer trade book valu expect limit roe
earn growth cours apart tax reform expect
low-single-digit sale growth japan us
risk rate price target
new product introduct could meaning boost sale growth japan
increas long-term interest rate japan could improv earn time
deep recess could caus renew slowdown growth us
currenc risk due estim earn japan
heavi ownership sub-debt bond european financi institut could lead
signific futur write-off although indic complet take
realiz loss european bank financi institut portfolio
asset-li mismatch risk
polit risk japan
found aflac inc financial-servic hold compani headquart
columbu ga compani got start columbu georgia home
paul john amo founder compani also father uncl
respect amo ceo last two decad oper may
world largest supplemental-health-insur businessth busi provid
coverag fill hole gap exist medic coverag subsidiari includ
american famili life assur compani nebraska-domicil life insur oper
countri japan largest busi compani oper
branch american famili life call aflac japan aflac inc complet
purchas continent american insur compani caic market
administ group insur insur broker name aflac group
million
parent compani oper elimin
growth oper earn
growth oper ep
fund alloc repurchas million
